Seonghae Yoon
Overview
Explore the profile of Seonghae Yoon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yoon S, Jeong S, Jung E, Kim K, Jeon I, Lee Y, et al.
Sci Rep
. 2021 Sep;
11(1):19150.
PMID: 34580385
To investigate pharmacokinetic and pharmacodynamic differences of zolpidem between males and females and their causes, including CYP3A4 activity. A single oral dose of zolpidem (10 mg) was administered to 15...
12.
Huh K, Kim E, Lee S, Yoo H, Yoon S, Yu K, et al.
Front Pharmacol
. 2021 May;
12:651790.
PMID: 34045962
Demonstration of bioequivalence (BE) is mandatory while developing generic drugs. The scientific concept of BE applies equally to different regulatory agencies. However, the application of the concept may differ for...
13.
Jang Y, Yoon S, Kim T, Lee S, Yu K, Jang I, et al.
Sci Rep
. 2021 Mar;
11(1):6370.
PMID: 33737678
This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events of...
14.
Suh K, Yoon S, Kim J, Yoon S, Kim J, Kim S, et al.
J Geriatr Oncol
. 2021 Mar;
12(6):922-929.
PMID: 33642225
Objectives: To investigate whether discontinuation of prophylactic dexamethasone by gradual dose de-escalation is practicable in older patients with cancer undergoing moderately emetogenic chemotherapy. Materials And Methods: This single-arm, feasibility study...
15.
Chun J, Song K, Lee D, Hwang J, Jung H, Heo E, et al.
Int J Med Inform
. 2021 Feb;
149:104403.
PMID: 33592353
Background: A vancomycin loading dose is recommended for the treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections. However, clinicians often do not adhere to these recommendations, mainly due to nephrotoxicity...
16.
Kim E, Kwon B, Park J, Chung J, Seo S, Park K, et al.
Br J Clin Pharmacol
. 2021 Feb;
87(9):3492-3500.
PMID: 33538008
Aims: Rifampicin is a key drug for the treatment of tuberculosis (TB). Little is known for the relationship between the rifampicin pharmacokinetics and genetic polymorphisms in the Asian population. We...
17.
Lee Y, Chae W, Yoon S, Chung J, Cho J
Transl Clin Pharmacol
. 2020 Jul;
28(2):73-82.
PMID: 32656158
Cytochrome P450 (CYP) 3A enzymes, the most important phase 1 drug-metabolizing enzymes, are responsible for 50% of the metabolism of clinically used drugs. CYP3A activity varies widely among individuals, which...
18.
Yoon S, Lee H, Ji S, Yoon S, Cho J, Chung J
Clin Pharmacol Drug Dev
. 2020 Mar;
10(1):68-77.
PMID: 32191400
Ursodeoxycholic acid (UDCA) is a secondary bile acid that is used to treat primary biliary cholangitis. Although UDCA has a hepatoprotective effect in some diseases, its benefit in nonalcoholic fatty...
19.
Kim H, Kang J, Park Y, Kim J, Kim M, Kim S, et al.
Pharmacol Res Perspect
. 2020 Mar;
8(2):e00568.
PMID: 32162844
We report a phase I pharmacological study of an oral formulation of CKD-516, a vascular-disrupting agent, in patients with refractory solid tumors. Twenty-seven patients (16 in the dose-escalation cohort and...
20.
Kim Y, Yoon S, Choi Y, Yoon S, Cho J, Jang I, et al.
Sci Rep
. 2019 Dec;
9(1):19410.
PMID: 31857620
A lack of information regarding whether genetic polymorphisms of SLCO1B1 and ABCG2 affect the pharmacokinetics (PKs)/pharmacodynamics (PDs) of rosuvastatin in elderly subjects prevents optimal individualized pharmacotherapy of rosuvastatin in clinical...